SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Results of AGM
Cambridge, UK, 16 December 2022 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer , held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Details of the voting results are shown in the table below.
|
Ordinary Resolutions |
Votes For |
% |
Votes Against |
% |
Votes Total |
% of ISC Voted |
Votes Withheld |
|
1. Receive and adopt Report of the Directors and financial statements for the year |
6,255,275 |
99.82 |
11,023 |
0.18 |
6,270,831 |
9.21 |
4,533 |
|
2. Receive and adopt Renumeration Committee report for the year |
5,232,943 |
85.28 |
902,951 |
14.72 |
6,270,831 |
9.21 |
134,937 |
|
3. Re-elect Dr John Reader as Director of the Company |
6,085,556 |
98.87 |
69,338 |
1.13 |
6,270,831 |
9.21 |
115,937 |
|
4. Appoint Shipleys LLP as auditor |
5,618,405 |
91.55 |
518,753 |
8.45 |
6,270,831 |
9.21 |
133,673 |
|
5. Directors' authority to allot new shares |
5,345,322 |
86.08 |
864,630 |
13.92 |
6,270,831 |
9.21 |
60,879 |
|
Special Resolution |
|
|
|
|
|
|
|
|
6. Directors' authority to allot equity securities for cash |
5,316,094 |
85.61 |
893,858 |
14.39 |
6,270,831 |
9.21 |
60,879 |
The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)
- Ends -
For further information, please contact:
|
Sareum Holdings plc Tim Mitchell, CEO / Alex Harrison, Investor Relations
|
01223 497700 |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Peel Hunt LLP (Joint Corporate Broker) James Steel / Oliver Duckworth
|
020 7418 8900 |
|
Hybridan LLP (Joint Corporate Broker) Claire Noyce
|
020 3764 2341 |
|
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki |
0203 709 5700 |
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is focused on advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors into clinical development as potential new therapies for autoimmune diseases (with an initial focus on psoriasis), respiratory symptoms arising from viral infections and cancer immunotherapy. Sareum is also eligible to receive certain milestone payments and future royalties on SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. SRA737 was licensed to Sierra Oncology, which was acquired by GSK in June 2022.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
